PM
SUPN icon

Parametrica Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Parametrica Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,194
Closed -$247K – 402
2017
Q4 		$247K Buy
+6,194
New +$245K 0.16% 275

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Parametrica Management's SUPN Position: Q1 2018 in Review

Parametrica Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2018, closing a stake of 6,194 shares — an estimated $247K sold.

Parametrica Management first reported a position in SUPN in Q4 2017 and held it in 1 quarter. The position peaked at $247K in Q4 2017. 312 funds tracked by Wall St. Rank hold SUPN as of Q1 2018.

  • Parametrica Management reported no remaining Supernus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Parametrica Management sold 6,194 Supernus Pharmaceuticals shares in Q1 2018, an estimated $247K.
  • Parametrica Management first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Parametrica Management's Supernus Pharmaceuticals position peaked at $247K in Q4 2017.
  • 312 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2018.

Based on Parametrica Management's 13F filing for Q1 2018, filed 24 Apr 2018.